Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
AMGN [NASD]
Amgen Inc.
IndexS&P 500 P/E24.33 EPS (ttm)6.53 Insider Own0.10% Shs Outstand759.61M Perf Week10.61%
Market Cap120.69B Forward P/E17.66 EPS next Y9.00 Insider Trans4.98% Shs Float758.78M Perf Month13.11%
Income5.01B PEG2.62 EPS next Q2.11 Inst Own81.50% Short Float1.48% Perf Quarter25.32%
Sales19.46B P/S6.20 EPS this Y20.30% Inst Trans-0.23% Short Ratio2.86 Perf Half Y42.35%
Book/sh32.12 P/B4.95 EPS next Y6.82% ROA7.70% Target Price144.90 Perf Year36.99%
Cash/sh34.48 P/C4.61 EPS next 5Y9.27% ROE22.00% 52W Range107.09 - 159.72 Perf YTD41.43%
Dividend2.44 P/FCF25.90 EPS past 5Y12.00% ROI10.50% 52W High0.78% Beta0.50
Dividend %1.54% Quick Ratio4.00 Sales past 5Y4.50% Gross Margin80.50% 52W Low50.31% ATR4.01
Employees20000 Current Ratio4.40 Sales Q/Q10.70% Oper. Margin33.80% RSI (14)78.48 Volatility2.12% 2.81%
OptionableYes Debt/Eq1.37 EPS Q/Q21.80% Profit Margin25.70% Rel Volume0.86 Prev Close158.88
ShortableYes LT Debt/Eq1.26 EarningsOct 27 AMC Payout32.60% Avg Volume3.92M Price160.97
Recom2.40 SMA2014.58% SMA5015.47% SMA20029.80% Volume2,635,559 Change1.32%
29-Oct-14Reiterated Argus Buy $140 → $185
28-Oct-14Reiterated RBC Capital Mkts Outperform $150 → $165
08-Sep-14Reiterated RBC Capital Mkts Outperform $138 → $150
04-Aug-14Reiterated Argus Buy $135 → $140
30-Jul-14Reiterated RBC Capital Mkts Outperform $125 → $138
18-Jul-14Reiterated Deutsche Bank Buy $144 → $149
23-Apr-14Reiterated Oppenheimer Perform $121 → $122
21-Mar-14Reiterated Barclays Equal Weight $115 → $130
31-Jan-14Reiterated Argus Buy $130 → $135
20-Nov-13Reiterated Deutsche Bank Buy $138 → $142
29-Aug-13Reiterated UBS Buy $121 → $124
27-Aug-13Reiterated Barclays Overweight $105 → $115
31-Jul-13Reiterated Oppenheimer Perform $100 → $109
24-Apr-13Reiterated Deutsche Bank Buy $108 → $115
15-Apr-13Reiterated Barclays Equal Weight $90 → $105
08-Apr-13Reiterated RBC Capital Mkts Outperform $95 → $105
25-Jan-13Upgrade Argus Hold → Buy $96
24-Jan-13Reiterated UBS Buy $96 → $98
12-Sep-12Downgrade Robert W. Baird Outperform → Neutral $84
10-Sep-12Upgrade UBS Neutral → Buy $80 → $96
30-Oct-14 08:55AM  Top Health Care and Biotech Stocks to Buy That Have Already Posted Earnings at 24/7 Wall St.
29-Oct-14 05:58PM  Today's Market Thorns, Roses, and All Time Highs... Yahoo Finance Blogs
05:00PM  Amgens operating margins have been flat despite revenue growth Market Realist
04:47PM  AMGEN INC Files SEC form 10-Q, Quarterly Report EDGAR Online
04:43PM  FOMC: Not necessarily more hawkish, but certainly appeared a bit less dovish Yahoo Finance Blogs
04:22PM  Stocks Trim Losses After Fed Report; Solarwinds Soars at Investor's Business Daily
03:29PM  Why Nomura Upgraded Amgen at Barrons.com
02:53PM  Amgen Up on Strategic Initiatives and 2015 Guidance Zacks
11:28AM  Biotech Stock Roundup: Beat & Raise Quarter for Amgen, Celgene, Alexion, Biogen Zacks
09:00AM  Third Point Partners ups stake in Amgen Market Realist
28-Oct-14 10:51PM  Amgen, bowing to hedge fund pressure, to cut up to 1,100 more jobs at Los Angeles Times +6.07%
07:09PM  Australian shares hit 6-week peak after US rally; Fed in focus at CNBC
05:58PM  Market Thorns, Roses, and All Time Highs... Yahoo Finance Blogs
04:52PM  [video]Stocks Rally Tuesday; Dow Posts Triple-Digit Gain, Topping 17,000 at TheStreet
04:25PM  US STOCKS-Wall St jumps 1 pct, S&P ends above key level Reuters
04:20PM  Amgen has attractive, high-growth assets Market Realist
02:18PM  Amgen Refuses To Split, But Plans Hearten Investors at Investor's Business Daily
01:55PM  Amgen climbs after strong sales figures at Financial Times
01:51PM  How Many? Amgen Rejects a Break Up, But Will Slash Another 1,100 Jobs at The Wall Street Journal
01:45PM  Amgen 2015 outlook tops estimates, no plan to split; shares jump Reuters
01:33PM  Amgen At All-Time High, Deutsche Bank Ups Price Target Benzinga
01:04PM  Health Care Stocks On The Rise With Help From 3 Stocks at TheStreet
12:33PM  Amgen to cut up to 1,100 more jobs at Los Angeles Times
12:24PM  Amgen (AMGN) Stock Is Climbing Today Following Earnings Release at TheStreet
12:04PM  Stocks Extend Gains As Alibaba, Tesla Rally at Investor's Business Daily
11:37AM  Amgen (AMGN) Earnings Report: Q3 2014 Conference Call Transcript at TheStreet
11:31AM  Amgen CEO: We're not splitting up at CNBC
11:29AM  Stocks gain; Nasdaq, S&P 500 positive for October at CNBC
11:00AM  [$$] Amgen, Under Pressure, Outlines Strategy at The Wall Street Journal
10:36AM  Stocks Launch In Climbing Mood; Amgen, Spirit Airlines Climbing at Investor's Business Daily
10:11AM  Amgen: Cost Cutting, Buybacks and No Split at Barrons.com
09:32AM  Amgen Rallies 3% After Announcing Growth And Capital Plans Benzinga
09:13AM  Amgen CEO: Not planning on split CNBC
09:07AM  Amgen's stock rises after company outlines capital allocation plans at MarketWatch
08:57AM  AMGEN INC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities EDGAR Online
08:51AM  Amgen 2015 forecast tops Street view; sees cost cuts, share buyback Reuters
08:50AM  Amgen Starts $2 Billion Share-Repurchase Plan, Raises Dividend at Bloomberg
08:48AM  Amgen Outlines Strategy, Growth Objectives And Capital Allocation Plans PR Newswire
08:10AM  Amgen Beats on Q3 Earnings & Revenues, Ups View Again Zacks
06:00AM  Amgen, Sanofi, Ono link with academia on proteins project Reuters
05:00AM  'Fast Money' Recap: Is It Still Worth Investing in Twitter? at TheStreet
12:25AM  Amgen Beats Earnings Estimates, What's Next for AMGN? Zacks
27-Oct-14 07:41PM  Amgen raises forecast as quarterly profit tops estimates at Los Angeles Times
07:00PM  Four Biotechs Lead Health Care Stocks In Big Cap 20 at Investor's Business Daily
06:56PM  Amgen Q3 Earnings Beat Estimates; Guidance Mixed at Investor's Business Daily
06:09PM  [$$] Higher Drug Sales Buoy Amgen Results at The Wall Street Journal
05:57PM  Amgen beats 3Q estimates while shrinking workforce AP
05:50PM  Amgen profit tops Wall Street expectations; raises 2014 outlook Reuters
05:30PM  Trader: Manitowoc has some explaining to do CNBC
05:16PM  Amgen Beats Q3 Earnings Estimates Benzinga
05:07PM  Amgen: Nice Beat, Still Questions at Barrons.com
05:04PM  Today's Market Thorns, Roses, and All Time Highs... Yahoo Finance Blogs
05:00PM  Amgen Inc Earnings Call scheduled for 5:00 pm ET today CCBN
04:33PM  Amgen Posts 52-Week High, Beats It Again After Earnings at 24/7 Wall St.
04:14PM  Amgen net drops, but adjusted earnings beat views at MarketWatch
04:09PM  AMGEN INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
04:08PM  Amgen profit tops Wall Street expectations; raises 2014 forecast Reuters
04:01PM  Amgen beats Street, raises full-year forecasts at CNBC
04:01PM  Amgen's Third Quarter 2014 Revenues Increased 6 Percent To $5.0 Billion And Adjusted Earnings Per Share (EPS) Increased 19 Percent To $2.30 PR Newswire
04:00PM  Energy prices, can't have it both ways: Trader CNBC
03:49PM  Earnings look ahead: Twitter & Amgen CNBC
08:19AM  #PreMarket Primer: Monday, October 27: ECB Stress Tests In-Line With Expectations Benzinga
07:36AM  Monsters under the bed threaten markets seasonal boost at MarketWatch
07:07AM  Q3 2014 Amgen Inc Earnings Release - After Market Close CCBN
24-Oct-14 03:45PM  Will Amgen (AMGN) Disappoint in the Q3 Earnings Season? Zacks
23-Oct-14 05:39PM  Amgen To Webcast 2014 Business Review Meeting On October 28 PR Newswire
04:05PM  Amgen Announces Webcast of 2014 Third Quarter Financial Results PR Newswire
02:30PM  Novartis' Secukinumab Receives Favorable FDA Panel Vote Zacks
07:10AM  The Zacks Analyst Blog Highlights: AbbVie, Amgen, Regeneron, Pharmacyclics and Repros Therapeutics Zacks
22-Oct-14 07:00PM  17 trades in 91 seconds CNBC
05:59PM  Fast Money Final Trade: HD, HYG, MRK, AMGN CNBC
05:01PM  Biotechs Show Fed Chief's Not Much Of A Stock Analyst at Investor's Business Daily
01:40PM  Amgen Gains as Third Point Suggests Split Zacks
11:59AM  Four Reasons Why Amgen Won't Break Up at Barrons.com
11:46AM  Amgens Boss Makes a Prime Breakup Target for Loeb at New York Times
11:36AM  Third Point's Daniel Loeb Tells Amgen it's Time to Break up at TheStreet
11:25AM  Bernstein Analyst Was First on Amgen Split---But Missed Its 20% Rally at The Wall Street Journal
11:22AM  Amgen: splitting hairs at Financial Times
10:18AM  Biotech Stock Roundup: AbbVie Calls off Shire Acquisition, Will Amgen Consider Breakup? Zacks
09:47AM  Add Amgen to the List of Activist Targets at Barrons.com
09:25AM  A.M. Roundup: New Managed ETFs from Global X, J.P. Morgan; Loeb Calls For Amgen Break Up at Barrons.com
09:23AM  [video] Dan Loebs Third Point Takes Aim at Amgen Break Up at Bloomberg
02:01AM  [$$] Amgen: $100 Billion Activist Target at The Wall Street Journal
21-Oct-14 07:56PM  Third Point urges Amgen to consider breakup at USA TODAY
07:36PM  Third Point urges Amgen to consider breakup AP
06:32PM  Hedge fund Third Point calls for splitting Amgen into two firms at Los Angeles Times
06:28PM  [$$] Third Point Wants Amgen to Explore Separation at The Wall Street Journal
05:54PM  Loeb urges Amgen to explore a break-up at Financial Times
05:42PM  The Market Thorns, Roses, and All Time Highs... Yahoo Finance Blogs
04:29PM  Daniel Loeb urges Amgen to split into two companies at Fortune
04:22PM  The Plan to Drive Amgen Shares Up Over 70% at 24/7 Wall St.
04:22PM  Third Point's Loeb urges breakup of biotech company Amgen Reuters
04:03PM  Third Point, Loebs Hedge Fund, Urges Amgen to Consider a Breakup at New York Times
03:59PM  One Reason eBay (EBAY) Stock Is Up Today at TheStreet
03:42PM  Third Point wants Amgen to explore separation at MarketWatch
03:41PM  Amgen Statement Regarding Third Point Investment PR Newswire
03:19PM  Why Amgen (AMGN) Stock Is Rising in Afternoon Trading Today at TheStreet
03:02PM  Dan Loeb talks up Amgen stake; shares rise at CNBC
01:56PM  An Activist Hedge Fund Manager Thinks This $100 Billion Biotech Company Could Be Worth 80% More Business Insider
20-Oct-14 04:10PM  Amgen Sues Sanofi and Regeneron over PCSK9 Candidate Zacks
Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine worldwide. Its principal products include Neulasta, a pegylated protein for the treatment of chemotherapy-induced febrile neutropenia; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for treating the patients with non-myeloid malignancies; and Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. The company's principal products also comprise Aranesp and EPOGEN erythropoiesis-stimulating agents for the treatment of anemia and dialysis; XGEVA and Prolia for the prevention of skeletal-related events and treatment of postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in CKD patients on dialysis. Its other marketed products include Nplate, a thrombopoietic compound; and Vectibix, a human monoclonal antibody. The company's products in phase 3 clinical trial comprise Evolocumab, a human monoclonal antibody used for the treatment for dyslipidemia; Talimogene Laherparepvec for the treatment of unresected stage IIIB, IIIC, or IV melanoma; and Trebananib for the treatment of ovarian cancer. Its other product in development stage includes Ivabradine, an oral drug for chronic heart failure and stable angina in patients with elevated heart rates. The company markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and pharmaceutical wholesale distributors. It has collaborative arrangements with Pfizer Inc.; Glaxo Group Limited; AstraZeneca Plc.; Takeda Pharmaceutical Company Limited; UCB; and Bayer HealthCare Pharmaceuticals Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
COFFMAN VANCE DDirectorSep 05Option Exercise56.7920,0001,135,80041,623Sep 09 06:54 PM
Harper Sean EEVP, Research & DevelopmentAug 05Sale127.2914,0001,782,12659,503Aug 07 04:22 PM
Dittrich Thomas J.W.VP, Finance & CAOMay 21Option Exercise56.644,130233,91122,719May 22 05:15 PM
Dittrich Thomas J.W.VP, Finance & CAOMay 21Sale112.834,130465,98418,589May 22 05:15 PM
Bradway Robert AChairman, CEO and PresidentMay 12Buy111.7789499,919185,013May 12 08:33 PM
Michael A KellyActing CFOApr 28Sale110.452,065228,07241,041Apr 29 05:48 PM
de Carbonnel FrancoisDirectorMar 06Option Exercise54.4410,000544,35025,364Mar 07 05:23 PM
de Carbonnel FrancoisDirectorMar 06Sale126.691,000126,69018,343Mar 07 05:23 PM
BALTIMORE DAVIDDirectorFeb 26Option Exercise62.555,000312,75031,879Feb 26 08:28 PM
HENDERSON REBECCA MDirectorFeb 13Option Exercise62.4120,0001,248,16025,549Feb 14 04:34 PM
HENDERSON REBECCA MDirectorFeb 13Sale123.5320,0002,470,6805,549Feb 14 04:34 PM
Bradway Robert AChairman, CEO and PresidentFeb 12Option Exercise62.5565,0004,065,750216,040Feb 14 04:19 PM
AMGEN INC10% OwnerDec 17Buy7.00272,1421,904,994541,399Dec 18 06:09 PM